IMPLANTABLE DEVICE MANUFACTURING MODIFICATION 510(K) RULES WILL BE RELAXED UNDER REVISED FDA GUIDANCE ON 510(K)s FOR DEVICE CHANGES, PHILLIPS SAYS
This article was originally published in The Gray Sheet
Executive Summary
Implantable device manufacturing changes will require 510(k) clearance only in certain situations under revisions to FDA's 510(k) guidance document on device modifications, Philip Phillips, acting deputy director of the agency's Office of Device Evaluation, announced May 12 at an FDA/industry video conference.
You may also be interested in...
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.